The Natural Product 3',4',7,8- tetrahydroxyflavonoid Is a Potent
BRD4-BD2 Inhibitor in Suppressing Acute Myeloid Leukemia
Abstract
Background and Purpose: Bromodomain-containing protein 4 (BRD4) binds
acetylated lysine residues on the N-terminal tails of histones through
two bromodomains (BD1 and BD2) to regulate gene transcription.
Inhibiting one or both of the bromodomains results in different
phenotypes, suggesting BD1 and BD2 may have different functions. Here we
report the characterization of a natural product
3’,4’,7,8-tetrahydroxyflavonoid as a new and potent BRD4 inhibitor with
anti-cancer activities in vitro and in vivo. Experimental Approach:
AlphaScreen assays were performed to evaluate the inhibitory activities
of 3’,4’,7,8-tetrahydroxyflavonoid against the bromodomains. Crystal
structures of the compound bound to BRD4-BD1 or BD2 were solved to
reveal key binding features. MV4-11 in vitro cell culture model and
xenograft mouse models were used to examine the compound’s anti-cancer
activities. Western blotting, Immunofluorescence staining and RT-PCR
were used to investigate the mechanism(s) of the compound in suppressing
MV4-11 cell and tumor growth. Key Results:
3’,4’,7,8-tetrahydroxyflavonoid is ~100-fold more
selective for BRD4-BD2 (IC50=204 nM) than BD1. Co-crystal structures
show 3’,4’,7,8-tetrahydroxyflavonoid establishes more interactions in
BRD4-BD2 acetylated lysine binding pocket than BD1. Consistent with a
selective and high affinity with BRD4 bromodomains,
3’,4’,7,8-tetrahydroxyflavonoid treatment inhibited MV4-11 cell growth
and reduced AML tumor growth in vitro and in vivo, respectively.
Conclusion and Implications: Our data suggest
3’,4’,7,8-tetrahydroxyflavonoid as a potent selective inhibitor of
BRD4-BD2 with a novel chemical scaffold. Given its distinct chemical
structure from current BRD4 inhibitors, this compound may open the door
for a novel class of BRD4 inhibitors by serving as a lead compound.